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HPV infections in adolescents
Anna-Barbara Moscicki∗
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Abstract. Adolescents who are sexually active have the highest rates of prevalent and incident HPV infection rates with over
50–80% having infections within 2–3 years of initiating intercourse. These high rates reflect sexual behavior and biologic
vulnerability. Most infections are transient in nature and cause no cytologic abnormality. However, a small number of adolescents
will not clear the infection. Persistence of HPV is strongly linked to the development of high-grade squamous intra-epithelial
lesions (HSIL) and invasive cancer. The HSIL detected, however, does not appear to progress rapidly to invasive cancer.
Understanding the natural history of HPV in adolescents has shed light into optional treatment strategies which include watchful
observation of atypical squamous cells of undetermined significance (ASCUS) and low grade (LSIL). The association between
age of first intercourse and invasive cancer cannot be ignored. Consequently, initiating screening at appropriate times in this
vulnerable group is essential. In addition, with the advent of the HPV vaccine, vaccination prior to the onset of sexual activity is
critical since most infections occur within a short time frame post initiation.
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1. Introduction
One of the primary interests in human papillomavirus
(HPV) is tied to its unique oncogenic properties. Virtu-
ally all squamous cell invasive cancers of the cervix are
due to HPV infections. This striking finding is over-
shadowed by the commonness of this virus. HPV is
the most common sexually transmitted infection with
over 80% of sexually active women having been ex-
posed to the virus; most within 3–4 years after sex-
ual debut [1,2]. What still intrigues scientists is the
long gap between first infection (usually under 21 years
of age) and development of invasive cancer in women
several decades later. The high prevalence of HPV in
young women underscore the vulnerability of adoles-
cents to HPV but the low prevalence of cervical cancer
in this age group underscore the benign nature of initial
HPV infections. The high incidence of HPV in young
women plus the risk of invasive cancer and young age
at first intercourse suggests that there are behavioral
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and/or biologic risks that place the adolescent vulnera-
ble to not only HPV but persistent HPV infection. This
Chapter will discuss rates of acquisition in adolescents,
the natural history of infections and dysplasia, biologic
changes unique to adolescents and preferred treatment
recommendations for HPV in adolescents.
2. Incidence of HPV infection in adolescents
Most prevalence studies have demonstrated a 6–8
fold difference in HPV in younger women compared
to older. Rates have ranged from 12% to 56% in wom-
en under 21 years compared to 2–7% in women over
35 years of age [3–6]. Although this trend has been
relatively consistent in studies from developed coun-
tries, some countries show no increase across ages or a
second increase in older women. A study from Costa
Rica suggested that a second rise occurs after the age of
50 years; however, those rates still do not reach those
found in adolescents [7].
In a study reported in 2001, approximately 55% of
adolescents and young women acquired a cervical HPV
infection within 36 months after joining the study [8].
This was approximately within 5–7 years after initiat-
ing sexual intercourse. The greatest risk factor for hav-
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ing an incident infection was reporting a new sexual
partner. The risk was over 10 fold for each new partner
reported per month since the last visit 4 months ago. A
recent analysis of a similar cohort showed that of 620
adolescent and young women entered into the study,
37% had a prevalent cervical infection at baseline and
63.3% had an incident infection with a cumulative rate
of 75% within approximately 5–6 years after sexual de-
but (unpublished; personal communication Moscicki).
Another recent study examined 60 adolescents who
were asked to obtain weekly vaginal samples and had
cervical samples obtained at 3-month intervals [2].
Seventy seven percent were found to have a positive
sample for high risk HPV by 2.2 years of follow-up.
The most common type in this study was HPV 52;
38.3% had this type detected followed by HPV 16 with
a cumulative prevalence of 31.3%. If only cervical
infections were considered, 36% had a HR HPV type
detected within follow-up showing that half of the de-
tected HPV infections were from vaginal swabs only.
This is not surprising since many more samples from
the vagina were obtained in this study than from the
cervix. On the other hand, this finding also suggests
that many of the vaginal infections do not cause cervi-
cal infections and are not at risk for causing invasive
cervical cancer.
Age related incidence rates, however, have not been
consistent across all HPV types. In a recent study in
Costa Rica, women under 25 years of age were also
more likely to have infection with certain HPV types
but not all. It was noted that the alpha nine HPV types
(16 and 16 related types) were 2–3 times more common
in women under 25 years than women over 35 years [9].
However other types, such as type 61 or 71 increased
with increasing age. Of note, these HPV types (61 and
71) are not high-risk types suggesting their presence is
unimportant.
3. Vulnerability
The high incidence of HPV in adolescents has been
frequently blamed on sexual behavior. Adolescents are
much more likely than older women to have had multi-
ple partners within a shorter time frame, such as 6–12
months, than older women. The ease of HPV trans-
mission during sexual activity has been demonstrated
in numerous studies [8,10]. But in addition, to high
incidence rates, studies have shown that young age at
first intercourse is a risk for the development of cancer
in later life with a 3–4 fold increased risk of developing
Fig. 1. Colpophotograph of a 16 year old. Note the large area of
columnar epithelium in comparison to mature squamous epithelium
and abrupt squamo-columanr junction seen well onto the ectocervix.
invasive cancer if a women initiated intercourse under
the age of 18 years of age compared to 20 or older [11,
12]. These studies imply that there may be a biolog-
ic vulnerability related to the cervix of young women.
Certainly, the adolescent cervix in general is structural-
ly different than the adult women’s cervix [13]. Em-
bryologically, the cervix is initially lined by columnar
epithelium in utero. Urogenital squamous epithelium
replaces the columnar epithelium; however the replace-
ment is incomplete with an abrupt squamous-columnar
junction occurring on the ectocervix. The adolescent
enters puberty with relatively large areas of colum-
nar epithelium (Fig. 1) compared to the adult wom-
en. Due to increased estrogenic activity and resulting
acidity of the vagina, uncommitted generative cells of
the columnar epithelium begin to transform themselves
into squamous epithelium. Eventually, columnar ep-
ithelium transforms into squamous epithelium with a
new columnar junction occurring well into the os. The
predominant cell type in adults is the mature squamous
cell (Fig. 2). Both columnar and metaplastic squamous
cells are vulnerable to HPV probably for a variety of
reasons of which thinness of the epithelium may be one
factor (i.e. easy access to basal epithelial cells).
The transformation process is referred to as squa-
mous metaplasia. The importance of the transforma-
tion zone is known since all squamous cell cancers
of the cervix appear to arise within the transforma-
tion zone. Hence its vulnerability has been well es-
tablished. Since the process of squamous metaplasia
appears to be most active during adolescence, it may
represent a vulnerability to the establishment of HPV
infections. Triggers of squamous metaplasia include
sexual activity. Adolescents with exposure to multiple
sexual partners have cervixes that appear more adult
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Table 1
Cytologic categories using Bethesda
Bethesda Classification W.H.O. Classification
ASCUS (ASC) Atypia
undetermined significance (ASC-US)
cannot exclude HSIL (ASC-H)
LSIL (low-grade squamous intra-epithelial lesions) Condyloma
CIN 1
HSIL (high-grade squamous intra-epithelial lesions) CIN 2, CIN 3. Carcinoma in situ
Fig. 2. Colpophotograph of a 20 year old. Note the entire cervix is
covered by mature squamous epithelium with the squamo columnar
junction not visible.
like with small areas of ectopy [14,15]. It may be wom-
en with multiple partners are exposed to sexually trans-
mitted infections, which induce inflammation, repair
and metaplasia or semen itself may induce metaplasia.
Whatever the reason, rapidly proliferating cellular pop-
ulations of squamous metaplasia is presumably vulner-
able to HPV infection. HPV replication and patterns
of transcription are highly dependent on the differen-
tiation program of keratinocytes in the cervical squa-
mous epithelium. Therefore, it is somewhat intuitive
that squamous metaplasia is particularly favorable to
HPV survival. The environment is conducive to viral
replication, and possibly persistence. The high rates of
LSIL (see Table 1 for definition of LSIL) in adolescent
populations described below support this premise. The
protective barrier reflected by the mature squamous ep-
ithelium may be an important factor why adult wom-
en have lower rates of infection. Rates of LSIL range
from 2 to 14% [16–19] in adolescents while in older
women (> 30 years) the rates range from 0.6 to 1%. It
is important to emphasize, however, that HPV detec-
tion in adolescents is most commonly associated with
normal cytology. Over three-quarters of HPV-infected
adolescents have normal cytology [8]. Whether micro-
scopic abnormalities that remain undetected occur in
this group is still controversial. But either way, LSIL,
particularly in adolescents appear as benign as HPV
infections with normal cytology (see Natural histories
of HPV, LSIL, and HSIL in adolescents below).
The expression of viral proteins result in basal cell
proliferation, nuclear enlargment and abnormal mitotic
figures; all features of SIL [20]. A study of adolescent
women showed that those large amounts of metaplastic
change visible on colpopophotographs were more like-
ly to develop LSIL if infected with HPV than adoles-
cents with a relatively quiescent cervixes [21].
Few studies have attempted to examine biologic vul-
nerability to HPV infection. Castle et al. [22] found
that the alpha nine types (16, 31, 33, 35, 52, 58, and
67) were detected more commonly among women with
greater areas of ectopy. However, the opposite was
true of the 3 α 15 α types (61, 71, 72, 81, 83, 84, 89)
where prevalence increased with increasing maturity.
These authors suggested that the epithelial type helped
explain their findings.
4. Natural histories of HPV, LSIL and HSIL in
adolescents
Numerous studies have documented the transient na-
ture of HPV infection in adolescents and young wom-
en with 50% of women clearing an initially detected
infection within 6 months, and 90% clearing within 24
months [1,23,24]. It appears that certain HPV types,
such as HPV 16, clear more slowly than other high or
low risk types. Certainly, new infections of the same
type may occur blurring the true regression rates. There
is also evidence that having multiple types of HPVs
also slows clearance in adolescents [25,26]. Whether
this reflects a global defect in the immune response or
whether multiple HPV types act synergistically is un-
clear. These studies are also difficult to interpret since
the reproducabilty between laboratories of detecting
multiple types is low. C. trachomatis, a common in-
fection in adolescents, has been shown by one study to
enhance HPV persistence [27,28]. Since TH1 respons-
es are thought to be responsible for HPV clearance,
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the authors hypothesized that C. trachomatis in some
women may be associated with a Th2 type response
which in turns results in HPV persistence. This finding
with C. trachomatis has not been seen in other studies
of HPV persistence [29].
Certainly, many of the HPV infections result in LSIL
as mentioned above. The benign nature of LSIL is
demonstrated by its high rate of regression that paral-
lels the high rate of regression of HPV. A study of ado-
lescents and young women showed that 92% of LSIL
regressed within 36 months of observation [26]. Only
3 % of the adolescent women went onto develop HSIL.
Rates of regression of both HPV and LSIL among older
women appear to be less frequent; hence detection of
HPV or LSIL in older women (defined as > 30 years)
most likely reflects an already persistent infection and
an increased risk for HSIL.
The role of HPV persistence in the development of
HSIL has been established. However, how long persis-
tence is required for HSIL development remains con-
troversial. One of the problems in defining such risks
is that CIN 2 and 3 make up the term HSIL (see Ta-
ble 1) and the natural history of CIN 2 and 3 are likely
different. So studies using HSIL have found different
rates than those using CIN 2 or 3. Several countries that
have collected rates for CIN 3 show that rates of CIN 3
appear to peak in women aged 27–30 years; 7–10 years
after peak rate for HPV infections [30]. In comparison,
the risk of developing cytologic “HSIL” in adolescents
is probably equal that of women aged 20–30 years of
age. Mount and colleagues [19] review of cytology
found 0.7% of 15–19 year olds had HSIL compared to
0.8% of women aged 20-29 years and 0.7% in 30–39
year-olds. In a nationwide organized cervical screen-
ing program in Norway, 0.2% of 20,000 smears from
adolescents aged 15–19 years were reported as having
HSIL [17]. The reason for these differences is that the
rates of CIN 2 most likely out number the rates of CIN
3 in adolescents whereas in older women CIN 3 pre-
dominates. So these studies that detect HSIL cytology
in adolescents most likely reflect CIN 2 cases.
Given these limitations, it appears that CIN 1 and
2 develop shortly after infection in some women with
others taking up to 1–3 years before detection. Mosci-
cki et al. [8] found that 25% of women developed LSIL
within 3 years with the risk of of developing cytology
diminishing after 3 years. Woodman et al. [31] noted
that 3% of HPV negative and 7% of HPV positive ado-
lescents developed HSIL within 19 months of acquiring
HPV.
In general, the natural history of LSIL in adolescents
parallels that of HPV with few progressing to HSIL. In
a longitudinal study of LSIL, only 3% of adolescents
went onto HSIL within 3 years [26]. In contrast, a
retrospective chart review of adolescents< 19 years of
age with cytologic LSIL reported that 31% progressed
to HSIL by 36 months [32]. Since this study involved
chart reviews, it is not clear if the HSIL reflected new
lesions or actual progression of LSIL. In addition, on-
ly a third of the original cohort was followed for 36
months. These differences between studies may be a
matter of interpretation of cytology and histology or a
reflection of different population characteristics. None
of the studies found invasive cancer. In comparison
to older women, Cox et al. [33] showed that 12.8% of
older women will progress from LSIL or ASCUS/HPV
positive to HSIL within 2 years.
Studies of HSIL are few since carcinoma-in-situ is
part of what is now termed HSIL and there are ethical
concerns in monitoring these lesions without treatment.
In addition,
CIN 2 is not a very reproducible diagnosis by pathol-
ogists and there is considerable debate as to whether
CIN 2 behaves more like CIN 1 or more like CIN 3 [34].
The importance of these differences for adolescents is
that CIN 2 lesions make up the majority of HSIL while
CIN 3 is less common [16,19]. No studies to date are
available for progression of CIN 2 or 3 in adolescents.
However, prevalence studies in US adolescents have
consistently shown that adolescents rarely have inva-
sive cancer [16,19]. According to the most recent US
SEER statistics (1995–1999), the incidence of invasive
cancer in women under among 20 years of age is 0–
3 per million [35]. Little information is available on
the rare cases of invasive cancer such as presence of
immunodeficiency disorders.
5. Cervical cancer screening
The high rates of regression in adolescents of HPV
and LSIL have spurred a movement in the US to push
back the age when to initiate screening. Older guide-
lines included all adolescents once sexually active [36,
37]. Recently, guidelines were constructed on risk
behaviors (i.e. initiating sexual activity) and a time
frame [38]. Through cost effective modeling, it was
shown that initiating screening 3 years after the on-
set of sexual activity or 21 years of age, whichever
comes first, would be cost-effective. In addition, these
guidelines were felt to encompass screening in high-
risk groups (i.e. those initiating sexual activity at early
ages) [36,37].
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Although cervical cancer screening in adolescents
yield low benefits, the age limit to begin screening re-
mains controversial. As mentioned, US guidelines base
risk of cancer on sexual behavior. This type of screen-
ing is strategic in identifying the highest risk youth.
Although the recommendations were based on sexual
behavior reporting, most agree that a cap is needed for
women who are unwilling or unable to report sexual
activity. The upper age limit of 21 years used by the
American Cancer society was primarily based on expert
opinion. In the US, this age was considered a realistic
age for compliance and access to patients, particularly
that the US has no organized screening program. In
countries with organized screening such as the Unit-
ed Kingdom, new recommendations start screening at
25 years [39]. In contrast, Australia has new guide-
lines that recommend screening begin at the ages of 18
years, or one to two years after first sexual intercourse,
whichever is later [40]. Data show that some rare cas-
es of invasive cancer will occur in the 20–24 year old
group; hence precancers in this group would be missed
if screening begins after 20 years of age.
6. ASCUS and LSIL triage
The high rates of LSIL and HPV regression have
led to more reasonable guidelines for adolescents [41].
ASCUS triage with HPV testing has been incorporat-
ed into many triage schemes. However, recent study
of population performances show that up to 77% of
adolescents with ASCUS will be positive for high-risk
HPV types. This has called into question the use of
HPV triage in adolescent populations [42]. Repeat cy-
tology 6 to 12 months is now often favored over HPV
triage. Similar conservative observation of LSIL by
cytology is also recommended with repeat cytology 6
to 12 months later rather than immediate referral to
colposcopy [43]. Since ASCUS-HR HPV type has a
similar history as LSIL, similar strategies can be given
to these lesions if HPV testing is performed on the AS-
CUS smear. At first repeat cytology, HSIL or higher
should be referred for colposcopy. At second repeat cy-
tology, any abnormality on repeat cytology for ASCUS,
ASCUS HR, and LSIL follow-up leads to referral to
colposcopy. Because of the high rates of HPV infection
in adolescents, follow-up with HPV testing for any of
these lesions is of questionable value. No cost-effective
analysis for this age group has been performed.
Appearance of HSIL on cytology at any follow-up
visit should be referred to colposcopy.
Because of the frequency of HPV infections in ado-
lescents, HPV testing for primary screening is not rec-
ommended.
7. Treatment of SIL
Treatment of LSIL among adolescents is consid-
ered unwarranted. Recommendation for treatment of
HSIL for adolescents is similar to that of adults. Some
have recommended cryotherapy over LEEP for suit-
able cases (small accessible lesions) in adolescents be-
cause of the lower rate of complication associated with
cryotherapy. A recent meta-analysis of LEEP proce-
dures showed increased risk of preterm delivery, low
birth weight, and premature rupture of membranes [44].
In summary, HPV is undoubtedly the cause of cer-
vical cancer. However, HPV detection, specifically in
adolescents, is not an absolute marker of cervical can-
cer risk. Adolescents are at high risk of acquiring HPV
infection with over 50–80% having infections within
2–3 years of initiating intercourse. These high rates are
due either to sexual behavior, biologic vulnerability or
a combination of both. Most infections are transient in
nature and cause no cytologic abnormality. However,
a small number of adolescents will not clear the infec-
tion and develop HSIL. The HSIL detected, however,
does not appear to progress rapidly to invasive cancer
since cancers in this age group remain rare. Under-
standing the natural history of HPV in adolescents has
shed light into optional treatment strategies which in-
clude watchful observation of ASCUS and LSIL. The
association between age of first intercourse and inva-
sive cancer cannot be ignored. Consequently, initiating
screening at appropriate times in this vulnerable group
is essential. With the HPV vaccine on the horizon, it
will be essential to vaccinate children prior to the on-
set of sexual activity; prior to acquisition of HPV. Ac-
cordingly, adolescents who initiate sexual activity may
not have yet developed an HPV infection and should
receive vaccination as well. All adolescents vaccinated
must be counseled about the important of continued
cancer screening.
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